Therefore, we tested the role of feed-forward cytokine receptor signaling in BCG responses by blocking JAK1/2 using INCB0184224 (also known as Ruxolitinib, clinically approved for the treatment of myelofibrosis, and referred to here as JAKi). Here, JAK1 is linked to myelofibrosis.